Introduction
============

Amyloid precursor protein (APP)[\*](#fn1){ref-type="fn"} and presenilins (PSs) are key proteins in the pathogenesis of Alzheimer\'s disease ([@bib41]). PSs are multimembrane-spanning domain proteins, essentially located in the ER, the intermediate compartment, and the cis-Golgi region ([@bib53]; [@bib10]; [@bib2]; [@bib24]). Some evidence for the presence of minute amounts of PS at the cell surface has been provided ([@bib38]). APP is a type I transmembrane protein processed by secretases, resulting in the generation of various fragments, most notoriously the amyloid peptide (Aβ). Aggregation of this peptide is considered to be a central event in the process leading to Alzheimer\'s disease ([@bib41]). The β-secretase BACE (β-site amyloid cleaving enzyme) has been identified recently. It is an aspartyl protease cleaving APP at the NH~2~ terminus of the amyloid peptide sequence ([@bib52]). The α-secretase cleaves in the Aβ sequence itself, precluding further Aβ production. Several members of the ADAM family (a disintegrin and metalloprotease), i.e., TACE, MDC9, and ADAM10, have been implied in α-secretase processing of APP ([@bib6]; [@bib25]; [@bib27]). Finally, presenilin 1 (PS1)-dependent γ-secretase cleavage of APP releases the COOH terminus of the amyloid peptide ([@bib12]). PS-dependent γ-secretase activities are also involved in the processing of other integral membrane proteins like Notch and APLP-1 ([@bib13]; [@bib33]; [@bib43]; [@bib47]). This γ-secretase cleavage is a novel type of proteolytic processing, occurring in the hydrophobic environment of the cell membrane. In the case of Notch, the cleavage results in the release of its intracellular domain that regulates gene transcription in a process that has been called "regulated intramembrane proteolysis" ([@bib1]; [@bib5]).

Several lines of evidence have led to the hypothesis that PS is the γ-secretase. First, γ-secretase cleavage of APP and Notch is inactivated partially in PS1-deficient cells and completely in PS1/PS2 double--deficient cells ([@bib12], [@bib13]; [@bib43]; [@bib47]; [@bib20]; [@bib57]). Moreover, mutagenesis of one or two aspartyl residues located in transmembrane domain 6 or 7 results in dominant negative--like effects on γ-secretase cleavage, suggesting that these aspartates contribute to the active site of PS ([@bib55]). Some similarities with the prepilin peptidases has been taken as further evidence that the PS are proteases ([@bib45]). However, the strongest argument in favor for this idea comes from the observation that several compounds that inhibit γ-secretase bind specifically to PS ([@bib15]; [@bib28]; [@bib40]). Nevertheless, direct proof that the PS can hydrolyze peptide bounds is still lacking.

Remarkably, both Notch and APP apparently first need proteolytical trimming of their extracellular domain by TACE and α-/β-secretase, respectively, to become a substrate for PS/γ-secretase ([@bib12]; [@bib4]; [@bib32]; [@bib46]). These proteases are located downstream in the biosynthetic pathway and therefore both Notch and APP first have to leave the ER to become a substrate for PS/γ-secretase. Despite significant advances in our understanding of γ-secretase processing, it remains unclear how APP, after its cleavage by α- or β-secretase, becomes exposed to PS. Moreover, Aβ appears to be produced mainly in the endosomal compartment ([@bib26]; [@bib19]), whereas PS is abundantly present in the ER and intermediate compartment ([@bib53]; [@bib10]; [@bib2]; [@bib24]). This problem can be summarized as "the spatial paradox" ([@bib1]) and we now tackle this problem further by analyzing the processing of a series of APP-trafficking mutants in primary cortical neurons derived from PS1+/+ or PS1−/− mice. We analyzed the consequences of restricting APP trafficking to certain subcellular compartments for the generation of total Aβ and Aβ42. Constructs tested: (a) APP with deleted cytosolic tail (APP-Δct); (b) APP with a double lysine ER retention motif in its cytoplasmic tail (APP-KK); (c) APP with a cytoplasmic tail from the LDL receptor (APP-LDL); (d) APP truncated at the β-secretase cleavage site (APP-C99); and (e) APP-C99 with a double lysine (KK) motif. The APP-Δct is poorly reinternalized and stays for longer times at the cell surface ([@bib49]). The KK motif acts an ER-retrieval signal ([@bib23]; [@bib16]) and therefore APP-KK colocalizes abundantly with endogenous PS1 ([@bib35]; [@bib2]). The APP-LDL recycles between the endosomal system and the cell surface ([@bib2]). APP-C99 is a direct substrate for γ-secretase and after addition of the KK ER retention motif (APP-C99-KK) we anticipated creating an excellent substrate for PS1/γ-secretase. Overall, our data confirm the spatial paradox in the PS-is-γ-secretase hypothesis and provide evidence that the transfer of APP-C99 in a compartment downstream of the ER is needed in addition to processed PS1 to obtain γ-secretase activity in primary cultures of neurons.

Results
=======

Different APP-trafficking mutants ([Fig. 1](#fig1){ref-type="fig"}) were expressed in primary cortical neurons derived from PS1+/+ and PS1−/− littermate embryos. Metabolically labeled full-length APP and secretase-cleaved APP fragments were immunoprecipitated and analyzed by phosphorimaging as described in Materials and methods. For all constructs, protein expression levels are very similar in PS1+/+ and in PS1−/− cells ([Fig. 2](#fig2){ref-type="fig"} A). Both full-length wild-type and APP-LDL chimera run as a doublet ([Fig. 2](#fig2){ref-type="fig"} A) of ∼120 kD, corresponding to mature- and immature-glycosylated APP. The majority for both the APP-KK and APP-Δct recombinant proteins is, however, the immature protein. This is expected for APP-KK, as the dilysine motif actively retains the protein in pre-Golgi compartments. The stronger immature APP-Δct band could reflect the rapid processing of the mature form by α-secretase at the cell surface ([@bib50]). Next, we analyzed proteolytic fragments derived from the different APP mutants. Secretion of the soluble ectodomain after α- or β-secretase cleavage generated from the different trafficking mutants was not significantly altered by PS1 deficiency, although the APP-Δct, for instance, produced roughly twice as many APPs ([Fig. 2](#fig2){ref-type="fig"}). β-Cleaved COOH-terminal stubs (APP-CTF) derived from APP-WT accumulated strongly in PS1−/− neurons ([Fig. 2](#fig2){ref-type="fig"} B), confirming previous data ([@bib12]). Interestingly, the same relative accumulation was observed for APP-CTF derived from the APP-LDL chimera. Also, total Aβ secretion was severely decreased in PS1−/− neurons transduced for APP-WT and APP-LDL ([Fig. 2](#fig2){ref-type="fig"} B). Although the secretion of Aβ42 derived from APP-LDL is reduced by 80% in PS1+/+ neurons, in line with previous observations ([@bib26]; [@bib36]), the additional relative decrease caused by PS1−/− deficiency remained unaltered when compared with APP-WT ([Fig. 2, B and C](#fig2){ref-type="fig"}). Together, these data suggest that in the case of the APP-LDL chimera, the enhanced recycling in the endosomal limb does not directly influence PS1-dependent γ-secretase processing.

![**APP-trafficking mutants.** APP is schematically represented (APP-WT). The different relevant proteolytic fragments are indicated at the top. The ectodomain is detected by pAb207, the amyloid peptide region 1--16 is detected by pAb B7, region 1--5 by mAb 3D6, region 17--24 is detected by mAb4G8, and the last 20 amino acids of the COOH-terminal cytoplasmic tail are detected by pAb B11/4 and pAb 6687. α-, β-, and γ-secretase cleavage sites are indicated. In the APP-C99 construct, a supplementary Asp and Ala residue (DA) has been added to obtain cleavage by the signal peptidase at the β-secretase site (see [@bib29]). For further details see Materials and methods.](0104045f1){#fig1}

![**Processing of APP trafficking mutants in PS1**+**/**+ **and PS1**−**/**− **neurons.** (A) PS1+/+ or PS1−/− primary neuronal cultures were transduced with pSFV bearing APP-WT, APP-Δct, APP-KK, or APP-LDL as described, and metabolically labeled with \[^35^S\]methionine for 4 h at 37°C. Cell extracts (two top panels) and culture media (two bottom panels) were immunoprecipitated using the appropriate antibodies and analyzed on 10% or 4--12% NuPage gels. The position of the various APP fragments is indicated. Note that the APP-Δct holo-forms and COOH-terminal β-fragments migrate faster because the cytoplasmic domain is deleted, whereas the APP-LDL fragments migrates slower due to the large LDL receptor cytoplasmic domain. The COOH-terminal α-stub is not detected here because antibody B7 does not react with that fragment. (B) APP fragments from three independent experiments were quantified using PhosphorImaging and normalized to the level of expression of the APP holo-forms ([@bib11], [@bib12]; [@bib2]). Data obtained in the PS1−/− neurons are compared with the data obtained in the PS1+/+ neurons. This shows the relative effect of the absence of PS1 on each APP fragment separately. Since APP-Δct is processed by β-secretase to a limited extent only, the results displayed in [Fig. 3](#fig3){ref-type="fig"} are more significant for conclusions regarding the level of γ-secretase processing of this construct. (C) The secretion of Aβ42 was analyzed by ELISA. All results are normalized to the level secreted by PS1+/+ neurons transfected with APP-WT. Dark bars and light bars represent data obtained in PS1+/+ and PS1−/− neurons, respectively.](0104045f2){#fig2}

The reduction of β-cleaved APP-CTF in the APP-Δct--transduced wild-type neurons is accompanied by an 80% decrease in secretion of total Aβ and Aβ42 ([Fig. 2, A and C](#fig2){ref-type="fig"}). Moreover, no relative accumulation of β-cleaved APP-CTF in PS1−/− neurons was observed. All this can be explained by a predominant α-secretase cleavage of APP-Δct at or near the plasma membrane, as reflected by the increased secretion of APPs cleaved at the α-secretase site and the concomitant fivefold increase in p3 secretion ([Fig. 3](#fig3){ref-type="fig"}) . Interestingly, secretion of p3 is dramatically inhibited in the absence of PS1 ([Fig. 3](#fig3){ref-type="fig"}, bottom), indicating that α-stubs generated near or at the cell surface are still substrates for PS1-dependent γ-secretase processing. Therefore, the data on APP-Δct and APP-LDL clearly demonstrate that PS1 is needed for normal γ-secretase processing in the late Golgi region, at the cell surface, and in the endosomal compartments.

![**Secretion of p3 in PS1**+**/**+ **and** −**/**− **neurons expressing APP-**Δ**ct.** Neurons were transduced and metabolically labeled as above. Cell extracts (top) and culture media (bottom) were immunoprecipitated using pAb207 (holo-APP) or mAb4G8 (αAPPs and Aβ/p3). The intermediate band running between Aβ and p3 in cells transduced with APP-WT corresponds to the truncated Aβ generated by β-secretase cleavage at the Glu11 position ([@bib9]).](0104045f3){#fig3}

In contrast to the other mutants, the levels of APPs and of the COOH-terminal β-stubs generated from APP-KK are very low, confirming the low α- and β-secretase activity in the ER ([Fig. 2, A and B](#fig2){ref-type="fig"}). Accordingly, the total Aβ ([Fig. 2](#fig2){ref-type="fig"} B) and Aβ42 ([Fig. 2](#fig2){ref-type="fig"} C) secretion was also strongly reduced by 90%. However, when overexpressed in PS1−/− neurons, secretion of Aβ peptides was inhibited to the same extent as observed for peptides derived from APP-WT ([Fig. 2, B and C](#fig2){ref-type="fig"}).

To circumvent the need for "preactivation" of APP-KK by α- or β-secretase, we generated APP-C99-KK, corresponding to APP truncated at the β-secretase site ([@bib29]) and containing the KK-ER retention motif. When expressed in neurons, APP-C99-KK migrated with the same apparent molecular weight (10 kD) as the β-stub coming from APP-WT or the APP-C99 without KK motif ([Fig. 4](#fig4){ref-type="fig"} A; [@bib29]). APP-C99, like APP-WT, can be processed by α-secretase as reflected by the generation of α-APPCTF ([Fig. 4](#fig4){ref-type="fig"} A). APP-C99-KK, in contrast, is either not processed or processed very little by α- or β-secretase, confirming the specific retention of APP-C99-KK in the ER and cis-Golgi region. In line with the prediction that APP-C99 does not require α- or β-secretase cleavage to become a substrate for γ-secretase, an estimated sevenfold increase in total Aβ secretion ([Fig. 4](#fig4){ref-type="fig"} A) is observed. This effect is also observed with Aβ42, as detected by ELISA ([Fig. 4](#fig4){ref-type="fig"} B). The γ-secretase cleavage of APP-C99 is strongly inhibited in the absence of PS1 ([Fig. 4](#fig4){ref-type="fig"} C). Most surprisingly, however, was the observation that APP-C99-KK, which was also expected to be a substrate for PS1-γ-secretase because it is retained in the ER, turned out to yield little if any Aβ peptides ([Fig. 4, A and B](#fig4){ref-type="fig"}). It is unlikely that the KK motif directly interfered with the recognition of C99 by the γ-secretase complex, since the cytoplasmic tail of APP can be removed without affecting γ-secretase cleavage ([Fig. 3](#fig3){ref-type="fig"}). Moreover, C99KK becomes a substrate for γ-secretase under conditions specified below. Alternatively, the low Aβ secretion from neurons expressing APP-C99-KK might be explained by intracellular retention of newly formed Aβ peptides. Again, this could be ruled out, as no increased amounts of Aβ could be immunoprecipitated from cell extracts (result not shown, but see [Fig. 7](#fig7){ref-type="fig"} below).

![γ**-secretase processing of APP-C99 trafficking mutants in PS1**+**/**+ **and PS1**−**/**− **neurons.** (A) Cells extracts (top) and culture media (bottom) of neurons expressing APP-WT, APP-C99, or APP-C99-KK were immunoprecipitated using antibodies B11/4 against the APP COOH-terminal domain (top), or B7 against the amyloid region. Arrows on the gels indicate the position of the various APP fragments. Notice the striking absence of Aβ generation with APP-C99-KK. The 6.5-kD stub seen with APP-C99 and APP-C99-KK is PS1-independent and probably not physiologically relevant, since it is never observed with APP-WT. (B) Aβ42 levels were measured by ELISA as in [Fig. 2](#fig2){ref-type="fig"} B. Results are expressed relatively to those obtained for PS1+/+ neurons transfected with APP-WT. NS, nonsignificant (values below detection limit). (C) Aβ-fragments were quantified using PhosphorImaging and normalized to the level of expression of the APP holo-forms (*n* = 3; mean ± SEM). Data obtained in the PS1−/− neurons are compared with the data obtained in the PS1+/+ neurons. This shows the relative effect of the absence of PS1 on Aβ production from APP-WT and from APP-C99. The Aβ signals obtained with APP-C99-KK are below detection limit.](0104045f4){#fig4}

![**BFA treatment partially restores** γ**-secretase processing of APP-C99-KK.** Neurons were transduced with SFV-APP-C99 or -APP-C99-KK and treated with or without 10 μM BFA for 4 h. Culture media and cell extracts were immunoprecipitated using antibody B7 and separated on 10% NuPage gels. Detection of secreted and intracellular Aβ was done by Western blotting using the W0-2 mAb raised against the NH~2~ terminus of the Aβ sequence ([@bib21]). Neurons transduced with SFV-APP-C99-KK were treated with BFA as above. Cell extracts were sequentially immunoprecipitated using antibody FCA42, specific for Aβ peptides ending at residue 42 and FCA40, specific for Aβ peptides ending at residue 42 ([@bib3]), and separated on 10% NuPage gels. After blotting, Aβ peptides were revealed using the WO-2 mAb as above.](0104045f7){#fig7}

Using confocal scanning microscopy, we confirmed that APP-C99-KK was effectively retained in the ER, as demonstrated by its colocalization with the ER marker protein BIP ([Fig. 5](#fig5){ref-type="fig"} , A--C), and to a more limited extent with the intermediate compartment marker ERGIC-53 ([Fig. 5](#fig5){ref-type="fig"}, G--I). Importantly, APP-C99-KK colocalized abundantly with PS1 ([Fig. 5](#fig5){ref-type="fig"}, D--F), indicating that the simple presence of PS1 is not sufficient for γ-secretase processing to occur. In this respect, it is important to note that we have demonstrated previously that PS1 in the ER is already processed towards NH~2~- and COOH-terminal fragments ([@bib2]). We next investigated the subcellular localization of APP-C99 in primary cortical neurons. APP-C99 is clearly not distributed in the ER ([Fig. 6](#fig6){ref-type="fig"} , A--C), as deduced from the complete lack of colocalization with BIP. Similarly, little if any colocalization was observed with ERGIC-53 marking the intermediate compartment (arrowheads in [Fig. 6, D--F](#fig6){ref-type="fig"}, including horizontal section \[arrow\]). Most surprisingly, however, was the observation that APP-C99 immunoreactivity also essentially did not distribute into the Golgi apparatus as demonstrated by GM130 staining ([Fig. 6](#fig6){ref-type="fig"}, G--I). Finally, and despite APP-C99 being a good γ-secretase substrate ([Fig. 4](#fig4){ref-type="fig"}), this fragment does not colocalize with PS1 (arrowheads and vertical section in [Fig. 6](#fig6){ref-type="fig"}, J--L). This is in clear contrast to the colocalization of PS1 with the inactive γ-secretase substrate APP-C99-KK (see also [Fig. 5](#fig5){ref-type="fig"}).

![**APP-C99-KK colocalizes with PS1 in the endoplasmic reticulum.** Hippocampal neurons transduced with SFV-APP-C99-KK were fixed 6 h postinfection and stained with an antibody against APP (A with pab 6687; D and G with mab 3D6) and BIP (B), PS1 (E), or ERGIC-53 (H). C, F, and I represent the merged pictures. APP-C99-KK abundantly colocalized with the ER-marker protein BIP and with PS1. Little if any colocalization was observed with ERGIC-53, a resident protein of the intermediate compartment. Detection of primary antibodies was done with Alexa 488-- and Alexa 546--conjugated goat anti--mouse or goat anti--rabbit secondary antibodies (1/1,000 diluted). Bar, 10 μm.](0104045f5){#fig5}

![**APP-C99 does not colocalize with PS1 and is essentially present in a BIP, ERGIC-53, and GM130 negative compartment.** SFV-APP-C99 transduced hippocampal neurons were fixed and the subcellular localization of APP-C99 (A and G with pAb 6687; D and J with mAb 3D6) was compared with established marker proteins of the ER (BIP in B), the intermediate compartment (ERGIC-53 in E), the Golgi apparatus (GM130 in H), and finally with PS1 (K). C, F, I, and L show merged pictures. For D--F and J--L, the arrows point to the position of the corresponding vertical sections. Immunodetection was done as in [Fig. 6](#fig6){ref-type="fig"}. APP-C99 immunoreactivity was mainly concentrated in discrete spots that did not colocalize with the ER (C for BIP and arrowheads in L for PS1), and the Golgi region (merged panel I). Occasionally minor colocalization with ERGIC-53 could be observed (arrowheads in D--F). Bar, 10 μm.](0104045f6){#fig6}

To test the hypothesis that a component of a more downstream subcellular compartment is needed to process APP-C99-KK in the ER, we treated neurons expressing APP-C99 or APP-C99-KK with brefeldin A (BFA), a drug that causes a rapid redistribution of the Golgi apparatus into the ER ([@bib30]). This treatment resulted in a drastic reduction in APP-C99--derived Aβ secretion, whereas no difference was observed in the case of APP-C99-KK ([Fig. 7](#fig7){ref-type="fig"} A). However, addition of BFA resulted in a strong increase in intracellular Aβ generated from APP-C99-KK, towards levels indistinguishable from those obtained in BFA-treated APP-C99--transduced cells. This suggests that some unknown factors required for γ-secretase activity are redistributed from the Golgi region to the ER, which appears to be sufficient to partially restore Aβ production from APP-C99-KK. It has been suggested that Aβ generated in the endoplasmic reticulum consists mainly of Aβ ending at residue 42 ([@bib7]; [@bib8]; [@bib19]; [@bib54]). Remarkably, although we detect little intracellular Aβ under our experimental conditions ([Fig. 7, A and B](#fig7){ref-type="fig"}), treatment with BFA induces the generation of Aβ peptides, ending at residue 40 as well as at residue 42 ([Fig. 7](#fig7){ref-type="fig"} B).

Discussion
==========

Previous studies ([@bib26]; [@bib19]; [@bib50]) have shown that Aβ can be generated at the cell surface and in the endosomes of neurons, where little, if any, PS1 is present ([@bib2]). The first aim of the current study was to investigate to what extent γ-secretase activity in these subcellular compartments depends indeed on PS1. To this end we expressed APP-Δct and APP-LDL, two previously characterized trafficking mutants of APP ([@bib35]; [@bib50]; [@bib2]), in neurons. APP-Δct lacks the endocytosis signals in the cytoplasmic domain of APP and is therefore only slowly internalized. Compared with APP-WT, APP-Δct is processed mainly by an α-secretase activity at the cell surface ([@bib42]; [@bib50]; [@bib2]). This results in the replacement of Aβ production by a roughly equal production of p3, the product of consecutive α- and γ-secretase activity ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), confirming that the APP-Δct construct indeed behaves as predicted. Therefore, p3 production from this substrate reflects mainly γ-secretase cleavage of the α-APPCTF at the cell surface. Expression of this construct in PS1-deficient neurons resulted in a strong decrease of p3, demonstrating that γ-secretase cleavage at the cell surface depends on PS1 ([Fig. 3](#fig3){ref-type="fig"}). Since αAPPs secretion is not affected in the absence of PS1 ([Fig. 3](#fig3){ref-type="fig"}), we rule out the possibility that the decreased p3 production is caused by decreased α-secretase activity in these PS1-deficient cells.

APP-LDL expression selectively increased Aβ40 secretion, as predicted from its preferential localization in the endosomes ([@bib26]; [@bib35]; [@bib36]). Again, in the absence of PS1, Aβ generation from APP-LDL strongly decreased, demonstrating that γ-secretase processing of APP in the endosomes depends on PS1. It should be noted that we have not been able to detect any endogenous PS1 immunoreactivity at the cell surface or in the endosomes of the neuronal cells used in the current study ([@bib2]).

We next investigated whether we could increase γ-secretase processing of APP in the ER and the intermediate compartment, which contain the bulk of PS1 immunoreactivity in these neurons. Although several authors have provided evidence that the ER is a production site of this peptide, in particular Aβ42 ([@bib7]; [@bib8]; [@bib19]; [@bib54]), we and others have not been able to confirm these observations ([@bib2]; [@bib22]; [@bib31]). As shown in [Fig. 2](#fig2){ref-type="fig"}, a severe decrease in both Aβ40 and Aβ42 secretion is observed when APP is retained in the ER by means of the double lysine retention motif (APP-KK). Since the retention of APP in the ER implies that cleavage by α- and β-secretase (residing in the TGN, cell surface, and endosomes) becomes strongly compromised, and since proteolytic trimming of the APP ectodomain is a prerequisite for further γ-secretase processing ([@bib46]), it seems logical that the APP-KK mutation results in a strongly decreased γ-secretase cleavage and inhibition of Aβ generation. It is by consequence difficult to interpret the data obtained with APP-KK in regard to γ-secretase sensitivity. Therefore, we generated the APP-C99 construct, which is a direct substrate for γ-secretase ([@bib29]), and added to it the double lysine ER retention motif. As shown in [Fig. 5](#fig5){ref-type="fig"}, this construct is indeed retained in the ER, where it codistributes abundantly with PS1. Although we expected increased Aβ production, no significant amount of Aβ could be precipitated from the wild-type neurons ([Fig. 4](#fig4){ref-type="fig"}; [@bib22]; [@bib31]). This result was even more significant, as neurons expressing APP-C99 secreted about seven times more total Aβ, or specifically Aβ42, than those expressing APP-WT. The possibility that the Aβ generated from APP-C99-KK is retained in the cells was ruled out, since no significant accumulation of cells associated Aβ could be demonstrated ([Fig. 7](#fig7){ref-type="fig"} A, lane 9, and B, lanes 2 and 5)The possibility that the KK motif directly interfered with γ-secretase cleavage was ruled out by two observations. First, it is clear from the results with APP-Δct that the cytoplasmic domain of APP is not involved in the processing of APP by γ-secretase. Second, treatment of the cell cultures with BFA could restore the processing of C99-KK, clearly demonstrating that the inhibitory effect of the KK mutations is a trans, and not a cis phenomenon ([Fig. 7](#fig7){ref-type="fig"}). It should be pointed out here that PS1 in the ER is already proteolytically processed by the "presenilinase" and present as PS1-CTF and PS1-NTF ([@bib2]), thus in the putative active conformation. It follows from these data that the simple colocalization of a substrate (APP-C99-KK) with its putative protease (PS1) is not sufficient for proteolytic cleavage.

We conclude that Aβ production, including Aβ42, can not occur directly in the ER and requires at least one factor derived from a post-ER compartment. This conclusion is corroborated by two important pieces of evidence from the current work. First, APP-C99, which is a good substrate for γ-secretase, is mainly localized in a PS1-, BIP-, and ERGIC53-negative subcellular compartment ([Fig. 6](#fig6){ref-type="fig"}). Although the characterization of this compartment requires further experimentation, this result suggests that at least the proteolytic cleavage of the APP-C99 substrate occurs in a non-ER compartment. The second, more important argument comes from the experiments using BFA. BFA is a drug that causes the redistribution of post-ER compartments into the ER ([@bib30]). Treatment with this drug was sufficient to restore partially γ-secretase processing of APP-C99-KK proving that at least one non-ER component is needed to activate γ-secretase in the ER ([Fig. 7](#fig7){ref-type="fig"}). BFA treatment results in γ-secretase processing of APP at position Aβ42, something which could possibly be anticipated based on current knowledge ([@bib7]; [@bib8]; [@bib19]; [@bib54]). Surprisingly, however, cleavage at position Aβ40 is also observed ([Fig. 7](#fig7){ref-type="fig"} B), which is believed to occur mainly in the late compartments of the secretory and in the endosomal limbs of the subcellular trafficking pathways ([@bib26]; [@bib19]; [@bib50]).

Summarizing, our data indicate that efficient γ-secretase cleavage of APP can occur in compartments that contain little, if any, PS1, and that no or little γ-secretase activity is observed in compartments where abundant (maturated) PS1 is residing. This is a surprising result since most of the data currently available imply that PS1 is closely involved in γ-secretase type enzymatic activity ([@bib12], [@bib13]; [@bib44], [@bib45]; [@bib47]; [@bib55]; [@bib15]; [@bib20]; [@bib28]; [@bib57]). The spatial paradox between PS1 localization and γ-secretase activity can be explained by two hypotheses: (a) the minute amounts of PS1 in post--cis-Golgi compartments are the active enzymes. This implies that in addition to activation by presenilinase, additional proteins from these compartments are needed to make PS1 enzymatically active; and (b) PS1 is actually not the γ-secretase but acts, probably in concert with other proteins in the ER and intermediate compartment, to dispatch APP or γ-secretase to the subcellular compartment where cleavage will occur. In this hypothesis, BFA treatment results in the relocalization of the catalytic subunit(s) of γ-secretase to the ER.

In support for the first hypothesis, evidence for the presence of minute amounts of PS1 in other compartments than the ER has been provided. In some studies, the specificity of the antibodies used can be questioned ([@bib14]), but in polarized cell types like MDCK cells ([@bib17]) or in specialized cell membranes like growth cones or lamellipodia ([@bib39]), some PS1 seems to be located near or at the cell surface. [@bib38] provided evidence that PS1 can travel in complex with Notch to the cell surface, albeit that this conclusion was based on a single type of experimental approach, i.e., cell surface biotinylation. Furthermore, the hypothesis that PS travels together with its substrates from the ER to the cell surface and becomes activated there is probably not tenable if one takes into account that the relative amount of PS1 to its substrates is extremely low ([@bib48]). If PS1 needs to accompany every substrate that it will cleave from the ER to the cell surface, it becomes, given the limited amounts of PS available in any cell type, difficult to understand why strong overexpression of APP does not saturate the system and does not lead to inefficient γ-secretase processing.

Although it remains impossible to exclude that minute amounts of PS1 in the endosomes or at the cell surface are the active enzymes, it is clear that this hypothesis raises several new questions that need to be addressed. In addition, the function of the "inactive" pool of PS1 in the ER also remains to be explained. From the BFA experiments it follows that at least one other component of a non-ER compartment is needed to obtain activated PS1. This component is not the elusive protease called "presenilinase" responsible for PS maturation, and most probably not nicastrin, since this protein is present in the ER ([@bib56]).

The second hypothesis, that PS1 is needed for the correct trafficking of γ-secretase and its substrates, finds some theoretical support in the analogy with the sterol regulatory element--binding protein (SREBP)--SCREB cleavage--activating protein (SCAP) complex and the regulation of the proteolytical cleavage of SREBP ([@bib5]). SCAP is, like PS1, an ER resident, multitransmembrane domain--containing protein and regulates the trafficking of the membrane-bound transcription factor SREBP to post-ER compartments. Upon cholesterol depletion, SREBP travels to the cis-Golgi, where a site 1 protease cleaves SREBP in its luminal domain. The remaining NH~2~-terminal, membrane-bound fragment then becomes a substrate for a site 2 protease that cleaves in the transmembrane domain of SREBP ([@bib37]; [@bib34]). The coupling of vesicular protein transport and proteolysis provides a stringent control on the activation of the system and it could be envisaged that PS1, like SCAP, provides a similar control on APP (and Notch) processing. However, it should be pointed out that in case of SREBP processing, SCAP regulates its luminal cleavage and that the site 2 intramembraneous cleavage occurs by default. In case of PS1, its role is limited to the regulation of the intramembraneous γ-secretase cleavage ([@bib12]).

In conclusion, our data indicate a complex relationship between APP trafficking and its processing by γ-secretase. Moreover, they directly question the exact role of PS1 in γ-secretase processing and demonstrate that at least one cofactor (in the first hypothesis) or the protease (in the second hypothesis) is located in a compartment downstream of the ER. In the future, reconstitution of γ-secretase processing of APP, by mixing extracts of purified ER fractions and post-ER compartments, should allow us to further define at a molecular level this highly intriguing proteolytic system.

Materials and methods
=====================

Neuronal cell culture
---------------------

Primary cultures of mixed cortical neurons derived from wild-type and PS1 knock-out littermates were generated as described previously ([@bib12]). In brief, total brain of 14-d-old embryos was dissected in HBSS medium (GIBCO BRL), trypsinized, and plated on dishes (Nunc) precoated with poly-[l]{.smallcaps}-lysine (Sigma-Aldrich). Cultures were maintained in neurobasal medium (GIBCO BRL) with B27 supplement (GIBCO BRL) and 5 μM cytosine arabinoside to prevent glial cell proliferation.

Semliki forest virus (SFV) constructs
-------------------------------------

The following modifications were made to the cDNA coding for human APP695 ([Fig. 1](#fig1){ref-type="fig"}): (a) deletion of the last 43 amino acids of the cytoplasmic tail (APP-Δct) as described in [@bib49]; (b) addition of a di-lysine motif (QM mutated to KK, APP-KK) by site-directed mutagenesis (Stratagene); (c) exchange of its cytoplasmic domain with that of the LDL receptor (APP-LDL); (d) full deletion of the APP ectodomain until the Asp1 amino acid of the amyloid peptide region (β-secretase site). An additional AspAla (DA) was cloned by site-directed mutagenesis (Stratagene) between the last amino acid of the signal sequence (Ala) and the first of the Aβ region ([@bib29]) (APP-C99). Site-directed mutagenesis was used to add the di-lysine motif (APP-C99-KK). Recombinant SFV containing the APP mutants were generated as described previously ([@bib11]).

Transduction and metabolic labeling of neuronal cell cultures
-------------------------------------------------------------

Recombinant SFV was diluted 10-fold in neurobasal medium and added to the culture dishes. After a 1-h incubation at 37°C, fresh neurobasal medium was added. After 2 h, cells were metabolically labeled in methionine-free MEM (GIBCO BRL) supplemented with B27 and 100 μCi/ml \[^35^S\]methionine (ICN Biomedicals). 10 μM BFA (Epicentre) was added when indicated. After 4 h, conditioned medium and cells were recovered. Cells were lysed in IP buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) and cleared by centrifugation. Labeled protein was immunoprecipitated using 25 μl protein G Sepharose and specific antibodies as indicated below and in [Fig. 1](#fig1){ref-type="fig"}. Immunoprecipitates were finally solubilized in 25 μl Nu-Page sample buffer (Invitrogen) and electrophoresed on 4--12% or 10% acrylamide NuPage Bis-Tris gels under reducing conditions and MES in the running buffer (Invitrogen). Results were analyzed using a PhosphorImager (Molecular Dynamics) and ImagQuaNT4.1. All data were normalized to the value obtained for the corresponding APP holoform to normalize for variations between culture dishes. The following antibodies were used ([Fig. 1](#fig1){ref-type="fig"}). Rabbit pAb B7 recognizes the first 17 amino acids of Aβ, B11 the last 20 amino acids of the APP COOH-terminal domain ([@bib11]), goat pAb 207 the APP ectodomain (provided by Dr. M. Savage, Cephalon, Inc., West Chester, PA), mAb 4G8 (Senetek) amino acids 17 to 24 of Aβ, and mab W0-2 the NH~2~-terminal region of Aβ (provided by Dr. Tobias Hartmann and Konrad Beyreuther, University of Heidelberg, Heidelberg, Germany) ([@bib21]). Antibodies FCA40 and FCA42 specifically precipitate Aβ peptides ending at residue 40 (γ40) or at 42 (γ42) and were provided by Dr. F. Checler (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) ([@bib3]).

Quantification of the A**β**42 peptide by ELISA
-----------------------------------------------

Levels of Aβ42 in conditioned media and cell lysates were quantified by a sandwich ELISA test ([@bib12]), according to published protocols ([@bib51]). In brief, samples were dried by speed vacuum (Savant), resuspended in 300 μl of sample diluent, and incubated on 96-well ELISA plates precoated with mAb 3D6 against Aβ. After washing, samples were incubated with a biotin-labeled anti-Aβ42 antibody mAb 21F12 that only recognizes the final two amino acids of the Aβ42 sequence, followed by streptavidine-HRP. After adding the HRP substrate, samples were measured spectrophotometrically using a Victor2 (Wallac) with a 450-nm filter. The Aβ42 concentration in the samples was calculated based on the Aβ42 standards sigmoid curve equation, and using Prism 3.0 (GraphPad Software).

Confocal microscopy
-------------------

Hippocampal neurons grown on poly-[l]{.smallcaps}-lysine--coated glass coverslips in the presence of a glial feeder layer ([@bib18]; [@bib11]) were transduced with SFV-APP-C99 or -C99KK. 4 h after transduction, cycloheximide (100 μg/ml) was added to block further protein synthesis. After 6 h, neurons were fixed in 120 mM phosphate buffer containing 4% paraformaldehyde (pH 7.3) and 4% sucrose, permeabilized in ice-cold methanol and acetone, and immunostained ([@bib2]). Recombinant APP-C99 was detected with pAb 6687 (gift of Dr. C. Haass, University of München, Germany) or mAb 3D6 (gift of Dr. Seubert, Elan Pharmaceuticals, San Francisco, CA). mAbs to BIP were purchased from Sigma. PAb B17.2 was used to detect endogenous PS1 ([@bib2]). The intermediate compartment and Golgi region were identified using anti-ERGIC-53, provided by Dr. J. Saraste (University of Bergen, Norway), and anti-GM130 (Transduction Laboratories), respectively. Alexa 488-- and Alexa 546--conjugated secondary antibodies were from Molecular Probes. BioRad MRC1024 confocal microscope and Adobe Photoshop^®^ 5.2 were used for final processing ([@bib2]).
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